One-Size-Fits-All Breast Cancer Screening Is Ending—Here's What's Replacing It

Breast cancer screening is undergoing a fundamental shift. Instead of recommending the same screening schedule for all women based on age, researchers have found that tailoring mammogram frequency to your personal risk level—determined by genetics, health history, and lifestyle—reduces advanced cancer diagnoses while sparing lower-risk women from unnecessary testing. This approach, tested on 46,000 women across the United States, could transform how doctors approach breast cancer prevention in the coming years.

Why Age Alone Isn't the Best Guide for Screening?

For decades, breast cancer screening guidelines have relied heavily on age as the primary factor in deciding how often women should get mammograms. But research has long shown that breast cancer risk varies dramatically from person to person—and age tells only part of the story. "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," said Dr. Laura J. Esserman, director of the UCSF Breast Care Center and lead author of the study published in JAMA in December 2025. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies."

The WISDOM study directly compared traditional annual mammography with a risk-based screening strategy. Researchers used validated risk models to evaluate participants based on multiple factors, then assigned them to four risk categories. The results showed that this personalized approach did not increase the rate of late-stage cancer diagnoses—meaning women screened less frequently were not at higher risk of missing advanced cancers.

How Does Risk-Based Screening Actually Work?

Under the personalized screening model tested in the WISDOM study, women were placed into four distinct risk categories, each with tailored screening recommendations:

• Lowest Risk Group (26% of participants): Women were advised to delay screening until age 50 or until a risk algorithm indicated their risk had reached that of a typical 50-year-old.
• Average Risk Group (62% of participants): Women received screening every two years instead of annually.
• Elevated Risk Group (8% of participants): Women underwent annual mammograms.
• Highest Risk Group (2% of participants): Women received screening twice yearly, alternating between mammography and MRI (magnetic resonance imaging), regardless of age.

Women identified as having elevated or highest risk also received personalized support beyond screening. This included access to an online decision-making tool focused on breast health, direct contact with a breast health specialist, and recommendations for lifestyle changes such as improving diet and increasing physical activity. Discussions about medications that can help reduce breast cancer risk were also part of the plan.

What Role Does Genetic Testing Play in This New Approach?

One of the most striking findings from the WISDOM study was the discovery that genetic risk extends far beyond family history. Researchers found that 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported no family history of the disease. Under current clinical guidelines, many of these women would never have been offered genetic testing in the first place.

The study evaluated both well-known genetic variants—such as BRCA1 and BRCA2, which significantly increase breast and ovarian cancer risk—and smaller DNA changes that can be combined into a polygenic risk score. This comprehensive approach improved the precision of risk predictions and resulted in 12% to 14% of participants being reassigned to a different risk category based on their genetic profile. "This is one of the first studies to offer genetic testing to all women, regardless of family history," explained Allison S. Fiscalini, director of the WISDOM study at UCSF. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention."

The significance of this finding cannot be overstated: it means that many women at genetic risk for aggressive breast cancers have been going unidentified under the old system, simply because they lacked a family history of the disease.

What Do Women Actually Think About Risk-Based Screening?

Perhaps the most telling sign that this approach represents a genuine shift in cancer care is patient preference. Among the 46,000 women in the WISDOM study, those who were not randomly assigned to a specific screening strategy were able to choose their preferred approach. An overwhelming 89% of these women opted for risk-based screening over the traditional age-based model. This strong acceptance suggests that women appreciate having their individual circumstances considered rather than being treated according to a one-size-fits-all protocol.

The study also found that the personalized approach was more efficient. "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," said Dr. Jeffrey A. Tice, a UCSF professor of medicine who specializes in developing breast cancer risk assessment tools. This means that healthcare systems can focus intensive screening and prevention efforts on the women who need them most, while reducing unnecessary testing for those at lower risk.

Researchers are continuing to refine this approach through the WISDOM 2.0 study, which is now enrolling participants. The goal is to better identify women who face a higher likelihood of developing aggressive breast cancers and provide them with screening and prevention strategies tailored to their long-term health needs. As these findings gain traction, breast cancer screening guidelines are likely to evolve significantly in the coming years—moving away from age-based recommendations and toward a more personalized, evidence-based model that considers your unique risk profile.